Nasdaq warns Standard BioTools (NASDAQ: LAB) on sub-$1.00 bid price

Rhea-AI Filing Summary

Insights

FAQ

Filing Exhibits & Attachments

Positive

Negative

8-K Event Classification

Key Figures

Key Terms

What Nasdaq issue did Standard BioTools Inc. (LAB) disclose?

How long does Standard BioTools (LAB) have to regain Nasdaq bid price compliance?

Does the Nasdaq notice immediately affect trading in Standard BioTools (LAB) stock?

Can Standard BioTools (LAB) get more time beyond October 19, 2026 to comply?

What steps might Standard BioTools (LAB) take to restore Nasdaq compliance?

Is there any guarantee Standard BioTools (LAB) will regain Nasdaq compliance?

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Standard BioTools Inc. received a notice from Nasdaq that its common stock no longer meets the exchange’s $1.00 minimum bid price requirement after trading below that level for 30 consecutive business days.

The stock continues to trade on the Nasdaq Global Select Market under “LAB” while the company has 180 calendar days, until October 19, 2026, to regain compliance by having a closing bid price at or above $1.00 for at least 10 consecutive business days. If all other listing standards are met, the company may seek an additional 180‑day period by transferring to the Nasdaq Capital Market. Potential remedies mentioned include a reverse stock split. The company intends to work toward restoring compliance but notes there is no assurance it will succeed or receive any extension.

None.

Nasdaq minimum bid price deficiency and delisting risk: Standard BioTools Inc. has received a Nasdaq notice that its shares no longer meet the $1.00 minimum bid price requirement, creating a defined cure period and potential future delisting if compliance is not restored.

Nasdaq bid-price deficiency creates delisting risk if not cured.

Standard BioTools Inc. has fallen out of compliance with Nasdaq’s $1.00 minimum bid price rule after 30 consecutive trading days below that level. This triggers a 180-day window to restore the closing bid to at least $1.00 for 10 straight business days.

The company’s shares remain on the Nasdaq Global Select Market during this period, so trading is unaffected in the near term. If other standards are met, management could move the listing to the Nasdaq Capital Market and obtain a second 180-day cure period.

The disclosure notes that actions such as a reverse stock split may be used to regain compliance. The company states its intention to restore compliance but explicitly warns there is no assurance of success or that Nasdaq staff will grant any additional extension.

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice or transferred its listing to a different exchange.

Nasdaq minimum bid price: $1.00 per share Non-compliance period: 30 consecutive business days Initial compliance window: 180 calendar days +3 more

6 metrics

Nasdaq minimum bid price $1.00 per share Threshold under Nasdaq Listing Rule 5450(a)(1) for continued listing

Non-compliance period 30 consecutive business days Period with closing bid below $1.00 that triggered deficiency

Initial compliance window 180 calendar days Time from April 20, 2026 to cure bid price deficiency

Compliance deadline October 19, 2026 End of initial 180-day period to regain minimum bid price

Required compliant trading period 10 consecutive business days Minimum period at or above $1.00 bid to regain compliance

Potential additional window Additional 180 days Possible extra period if transferred to Nasdaq Capital Market

Minimum Bid Price Requirement, Nasdaq Global Select Market, Nasdaq Capital Market, market value of publicly held shares, +1 more

5 terms

Minimum Bid Price Requirement financial

"below the $1.00 threshold established under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”)"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

Nasdaq Global Select Market financial

"continued listing on The Nasdaq Global Select Market"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

Nasdaq Capital Market financial

"transfer the listing of its common stock to The Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

market value of publicly held shares financial

"meet the continued listing requirement for the market value of publicly held shares"

The market value of publicly held shares is the total dollar worth of a company’s shares that are available to outside investors, calculated by multiplying the current market price by the number of shares held by the public (the “float”). It matters because it tells investors how much of the company is actually tradable and how the market is pricing that tradable portion—like a price tag on the items on a store shelf, it affects liquidity, volatility and how easy it is to buy or sell a meaningful stake.

reverse stock split financial

"for example, by implementing a reverse stock split, if necessary"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

Understanding 8-K Material Events →

04/24/2026 - 04:15 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): April 20, 2026

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)


Delaware (State or other jurisdiction of incorporation)	001-34180 (Commission File Number)	77-0513190 (I.R.S. Employer Identification Number)
50 Milk Street, 10th Floor Boston, Massachusetts 02109
(Address of principal executive offices and zip code)
(650) 266-6000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, $0.001 par value per share	LAB	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On April 20, 2026, Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) indicating that the Company did not meet the minimum bid price requirement set forth in Nasdaq’s Listing Rules for continued listing on The Nasdaq Global Select Market. The Notice follows a 30-day period during which the Company’s share price closed below the $1.00 threshold established under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). Under Nasdaq Listing Rule 5810(c)(3)(A), the occurrence of a closing bid price below $1.00 per share for a period of 30 consecutive business days triggers an automatic compliance period of 180 calendar days.

The Notice has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Select Market, which will continue to trade uninterrupted on Nasdaq under the ticker “LAB”. The Notice also does not affect the ongoing business operations of the Company or its reporting requirements with the Securities and Exchange Commission.

The Company now has a period of 180 calendar days from the date of the Notice, or until October 19, 2026, to regain compliance with the Minimum Bid Price Requirement for a minimum of 10 consecutive business days. Should the Company meet all other continued listing standards for The Nasdaq Global Select Market, the Company may be eligible for an additional 180-day compliance period (unless the Staff exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H)). To qualify, the Company would need to transfer the listing of its common stock to The Nasdaq Capital Market and meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards, with the exception of the Minimum Bid Price Requirement. To effect such a transfer, the Company would also need to pay an application fee to Nasdaq and would need to provide written notice to the Staff of the Company’s intention to cure the deficiency during the additional compliance period, for example, by implementing a reverse stock split, if necessary.

The Company intends to work toward restoring compliance within the prescribed timeframe. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or that the Staff will grant the Company a further extension of time to regain compliance, if applicable.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

Standard BioTools disclosed it no longer meets Nasdaq’s $1.00 minimum bid price requirement after 30 consecutive business days below that level. Nasdaq issued a deficiency notice, starting a formal compliance period while the stock continues trading on the Nasdaq Global Select Market.

Standard BioTools has 180 calendar days from April 20, 2026, until October 19, 2026, to regain compliance. It must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during this period to cure the deficiency.

The notice has no immediate effect on trading. Standard BioTools’ common stock continues to trade uninterrupted on the Nasdaq Global Select Market under the ticker “LAB,” and the company’s ongoing business operations and SEC reporting obligations remain unchanged during the current compliance period.

If it meets all other listing standards, Standard BioTools may qualify for an additional 180-day compliance period. To do so, it would need to transfer its listing to the Nasdaq Capital Market and satisfy initial listing criteria other than the minimum bid price requirement.

The company mentions potentially curing the deficiency by implementing a reverse stock split, if necessary. It must also notify Nasdaq in writing of its intent to cure and, in the case of a market transfer, pay an application fee and meet applicable continued listing standards.

No. Standard BioTools states it intends to work toward restoring compliance within the prescribed timeframe but cautions there can be no assurance it will regain compliance or that Nasdaq staff will grant any further extension if needed.

April 24, 2026

STANDARD BIOTOOLS INC.

/s/ Alex Kim

Chief Financial Officer

1 document